Drug Profile
Research programme: autoimmune disorders therapy - BioFocus/Ono Pharmaceutical
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator BioFocus DPI; Ono Pharmaceutical
- Developer BioFocus DPI
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Autoimmune-disorders in United Kingdom
- 31 Mar 2014 BioFocus DPI has been acquired by Charles River Laboratories
- 13 Jan 2011 Early research in Autoimmune disorders in United Kingdom (unspecified route)